Background: Previous randomized trials have showed the superiority of Paclitaxel-eluting stent over bare metal stent in angiographic and clinical outcomes. Coroflex Please stent is a newly developed drug eluting stent using the Coroflex stent platform combined with the drug paclitaxel contained in a polymer coating. PECOPS I trial, one-arm observational study, showed that the clinical and angiographic outcomes of Coroflex Please stent were within the range of those of Taxus, the 1st generation paclitaxel-eluting stent (PES). However, there have been no studies directly comparing the Coroflex Please stent with the Taxus Liberte stent that is the newest version of Taxus. Therefore, prospective, randomized trial is required to demonstrate the non-inferiority of Coroflex Please stent compared with Taxus Liberte stent in a head-to-head manner.
Methods: In the comparison of Efficacy between COroflex PLEASe ANd Taxus stent(ECO-PLEASANT) trial, approximately 900 patients are being prospectively and randomly assigned to the either type of Coroflex Please stent and Taxus Liberte stent via web-based randomization. The primary endpoint is clinically driven target vessel revascularization at 9 months. The secondary endpoints include major cardiac adverse events, target vessel failure, stent thrombosis and angiographic efficacy endpoints.
Discussion: The ECO-PLEASANT trial is the study not yet performed to directly compare the efficacy and safety of the Coroflex Please versus Taxus Liberte stent. On the basis of this trial, we will be able to find out whether the Coroflex Please stent is non-inferior to Taxus Liberte stent or not.
Trial Registration: ClinicalTrials.gov number, NCT00699543.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773780 | PMC |
| http://dx.doi.org/10.1186/1745-6215-10-98 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serial Dilation and Intentional Fracturing of Stents in Congenital Heart Disease-Benchside Tests and Initial Clinical Results.
Catheter Cardiovasc Interv
January 2025
Department of Pediatric Cardiology and Congenital Heart Disease, German Heart Center Munich, Technische Universität München, München, Germany.
Background: There is some reluctance to implant stents in small children due to concerns regarding outgrowing the maximal stent diameter during follow-up.
Aim: Evaluation of a treatment strategy on the bench side, including intentional stent fracturing, and description of our initial clinical experience.
Methods: A series of benchside tests was performed with small stents, in which the stents were dilated above the rated diameters until they ultimately fractured.
Case report of spontaneous coronary artery dissection in a 50‑year‑old man.
BMC Cardiovasc Disord
August 2024
Clinical Research Development Unit, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Background: Spontaneous Coronary Artery Dissection (SCAD) is an acute coronary event of uncertain origin. SCAD occurs when the coronary artery wall dissects non-traumatically and non-atherosclerotically, leading to the formation of an intramural hematoma or intimal tear, ultimately compressing and restricting the true lumen, or even occluding it. The management of SCAD remains controversial despite modern imaging techniques.
View Article and Find Full Text PDFNearly catastrophe coronary perforation: Is it second drug-eluting stent effective?
Narra J
April 2024
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.
Coronary artery perforation (CAP) is an uncommon yet serious complication. Although severe perforations (Ellis III) have become more frequent, the overall mortality rate associated with perforations (7.5%) has decreased in recent years.
View Article and Find Full Text PDFBiodegradable Polymer Versus Polymer-Free Ultrathin Sirolimus-Eluting Stents: Analysis of the Stent Arm Registry From the HOST-IDEA Randomized Trial.
Circ Cardiovasc Interv
July 2024
Cardiovascular Center, Seoul National University Hospital, Republic of Korea (J.-K.H., S. Yang, D.H., S.-H. Park, J. Kang, H.-M. Yang, K.W. Park, H.-J. Kang, B.-K.K., H.-S. Kim).
Article Synopsis
- The study aimed to compare the clinical outcomes of two third-generation drug-eluting stents: the Coroflex ISAR and the Orsiro.
- It was conducted as part of the HOST-IDEA trial, which originally involved dual antiplatelet therapy duration but shifted to a registry format for stent comparison, ultimately including 328 patients randomized between the two stents.
- Results showed that patients with the Coroflex ISAR stent had a significantly higher rate of target lesion failure compared to those with the Orsiro stent, with revascularization being a major factor for this difference.
A more-Comers populAtion trEated with an ultrathin struts polimer-free Sirolimus stent: an Italian post-maRketing study (the CAESAR registry).
Front Cardiovasc Med
January 2024
Division of Cardiology, Università Degli Studi di Napoli Federico II, Napoli, Italy.
Article Synopsis
- - The study investigates the safety and effectiveness of the ultrathin Coroflex ISAR NEO polymer-free sirolimus-eluting stent (PF-SES) for patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), addressing concerns about long-term issues with traditional drug-eluting stents.
- - Conducted as a multicenter, prospective registry in Italy, the CAESAR study evaluated 425 patients, focusing on outcomes such as target-lesion revascularization (TLR) and major adverse cardiovascular events (MACE) over one year.
- - Results showed excellent clinical outcomes, with only 0.5% needing additional procedures for ischemia-induced TLR and a low rate of
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!